DOI: 10.3724/SP.J.1263.2011.00230

Journal of Geriatric Cardiology 2011/8:4 PP.230-242

Nitric oxide and geriatrics: Implications in diagnostics and treatment of the elderly

The nation’s aging population is growing rapidly. By 2030, the number of adults age 65 and older will nearly double to 70 million. Americans are living longer and older adults can now live for many years with multiple chronic illnesses but with a substantial cost to health care. Twenty percent of the Medicare population has at least five chronic conditions i.e., hypertension, diabetes, arthritis, etc. Studies in experimental models and even humans reveal that constitutive production of nitric oxide (NO) is reduced with aging and this circumstance may be relevant to a number of diseases that plague the aging population. NO is a multifunctional signaling molecule, intricately involved with maintaining a host of physiological processes including, but not limited to, host defense, neuronal communication and the regulation of vascular tone. NO is one of the most important signaling molecules in our body, and loss of NO function is one of the earliest indicators or markers of disease. Clinical studies provide evidence that insufficient NO production is associated with all major cardiovascular risk factors, such as hyperlipidemia, diabetes, hypertension, smoking and severity of atherosclerosis, and also has a profound predictive value for disease progression including cardiovascular and Alzheimers disease. Thirty plus years after its discovery and over 13 years since a Nobel Prize was awarded for its discovery, there have been no hallmark therapeutic breakthroughs or even NO based diagnostics. We will review the current state of the science surrounding NO in the etiology of a number of different diseases in the geriatric patient. From these observations, it can be concluded that enzymatic production of NO declines steadily with increasing age in healthy human subjects. Implementing strategies to diagnose and treat NO insufficiency may provide enormous benefit to the geriatric patient.

Key words:nitrite,nitrate,cardiovascular disease,Alzheimer’s disease,bloodflow,circulation

ReleaseDate:2014-07-21 16:04:42

1 Stuehr D, Marletta MA. Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proc Natl Acad Sci USA 1985; 82: 7738-7742.

2 Hibbs JB Jr, Taintor RR, Vavrin Z. Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 1987; 235: 473-476.

3 Arnold WP, Mittal CK, Katsuki S, et al. Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 1977; 74: 3203-3207.

4 Ignarro LJ, Buga GM, Wood KS, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA: 9265-9269.

5 Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetycholine. Nature 1980; 288: 373-376.

6 Garthwaite J, Charles SL, Chess-Williams R. Endothelium- derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature 1988; 336: 385-388.

7 Foster MW, McMahon TJ, Stamler JS. S-Nitrosylation in health and disease. Trends Mol Med 2003; 9: 160-168.

8 Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-142.

9 Liu Q, Gross SS. Binding sites of nitric oxide synthases. Methods Enzymol 1996; 268: 311-324.

10 Schulman SP, Becker LC, Kass DA. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 2006; 295: 58-64.

11 Cylwik D, Mogielnicki A, Buczko W. L-arginine and cardiovascular system. Pharmacol Rep 2005; 57: 14-22.

12 Taddei S, Virdis A, Ghiadoni L. Age-related reduction of NO availability and oxidative stress in humans. Hypertension 2001; 38: 274-279.

13 Nitrogen Cycling in Bacteria: Molecular Analysis; James WB, Ed.; Caister Acedemic Press: Norfolk, 2011.

14 Nitrite and Nitrate in Human Health and Disease (Nutrition and Health); Bryan NS, Loscalzo J, Eds.; Humana Press: New York, 2011.

15 Guzik TJ, Mussa S, Gastaldi D et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002; 105: 1656-1662.

16 Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006; 113: 1708-1714.

17 Lundberg JO, Weitzberg E, Cole JA, et al. Nitrate, bacteria and human health. Nat Rev Microbiol 2004; 2: 593-602.

18 Feelisch M, Fernandez BO, Bryan NS, et al. Tissue processing of nitrite in hypoxia: An Intricate interplay of nitric oxide-generating and scavenging systems. J Biol Chem 2008; 283: 33927-33934.

19 Bryan NS, Rassaf T, Maloney RE et al. Cellular targets and mechanisms of Nitros(yl)ation: An insight into their nature and kinetics in vivo. Proc Natl Acad Sci USA 2004; 101: 4308-4313.

20 Zweier JL, Wang P, Samouilov A, et al. Enzyme-independent formation of nitric oxide in biological tissues. Nat Med 1995; 1: 804-809.

21 Bryan NS. Nitrite in nitric oxide biology: Cause or consequence? A systems-based review. Free Radic Biol Med 2006; 41: 691-701.

22 Walters CL, Casselden RJ, Taylor AM. Nitrite metabolism by skeletal muscle mitochondria in relation to haem pigments. Biochim Biophys Acta 1967; 143: 310-318.

23 Kozlov AV, Staniek K, Nohl H. Nitrite reductase activity is a novel function of mammalian mitochondria. FEBS Lett 1999; 454: 127-130.

24 Cosby K, Partovi KS, Crawford JH, et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med 2003; 9: 1498-1505.

25 Li H, Samouilov A, Liu X, et al. Characterization of the effects of oxygen on xanthine oxidase-mediated nitric oxide formation. J Biol Chem 2004; 279: 16939-16946.

26 Webb A, Bond R, McLean P, et al. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. Proc Natl Acad Sci USA 2004; 101: 13683-13688.

27 Kleinbongard P, Dejam A, Lauer T, et al. Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med 2003; 35: 790-796.

28 McKnight GM, Smith LM, Drummond RS, et al. Chemical synthesis of nitric oxide in the stomach from dietary nitrate in humans. Gut 1997; 40: 211-214.

29 Dejam A, Hunter CJ, Schechter AN, et al. Emerging role of nitrite in human biology. Blood Cells Mol Dis 2004; 32: 423-429.

30 Gladwin MT, Schechter AN, Kim-Shapiro DB, et al. The emerging biology of the nitrite anion. Nat Chem Biol 2005; 1: 308-314.

31 Bryan NS, Fernandez BO, Bauer SM, et al. Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues. Nat Chem Biol 2005; 1: 290-297.

32 Pluta RM, Dejam A, Grimes G, et al. Nitrite infusions to prevent delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage. JAMA 2005; 293: 1477-1484.

33 Hunter CJ, Dejam A, Blood AB, et al. Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator. Nat Med 2004; 10: 1122-1127.

34 Hardwick JB, Tucker AT, Wilks M, et al. A novel method for the delivery of nitric oxide therapy to the skin of human subjects using a semi-permeable membrane. Clin Sci (Lond) 2001; 100: 395-400.

35 Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite- nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 2008; 7: 156-167.

36 Bryan NS, Calvert JW, Elrod JW, et al. Dietary nitrite supplementation protects against myocardial ischemia-reperfusion injury. Proc Natl Acad Sci USA 2007; 104: 19144-19149.

37 Duranski MR, Greer JJ, Dejam A, et al. Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest 2005; 115: 1232-1240.

38 Tsuchiya K, Kanematsu Y, Yoshizumi M, et al. Nitrite is an alternative source of NO in vivo. Am J Physiol Heart Circ Physiol 2005; 288: H2163-H2170.

39 Larsen FJ, Ekblom B, Sahlin K, et al. Effects of dietary nitrate on blood pressure in healthy volunteers. N Engl J Med 2006; 355: 2792-2793.

40 Webb AJ, Patel N, Loukogeorgakis S, et al. Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. Hypertension 2008; 51: 784-790.

41 Zand J, Lanza F, Garg HK. All-natural nitrite and nitrate containing dietary supplement promotes nitric oxide production and reduces triglycerides in humans. Nutr Res 2011; 31: 262-269.

42 Duncan C, Dougall H, Johnston P, et al. Chemical generation of nitric oxide in the mouth from the enterosalivary circulation of dietary nitrate. Nat Med 1995; 1: 546-551.

43 Björne HH, Petersson J, Phillipson M, et al. Nitrite in saliva increases gastric mucosal blood flow and mucus thickness. J Clin Invest 2004; 113: 106-114.

44 Aranke M, Bryan NS, Mian AI. Towards nitric oxide based diagnostics: call to action. Trends Mol Med 2011; In press.

45 Patel S, Celermajer DS. Assessment of vascular disease using arterial flow mediated dilatation. Pharmacol Rep 2006; 58 Suppl: S3-S7.

46 Tang Y, Jiang H, Bryan NS. Nitrite and nitrate: cardiovascular risk-benefit and metabolic effect. Curr Opin Lipidol 2011; 22: 11-15.

47 Bryan NS, Grisham MB. Methods to detect nitric oxide and its metabolites in biological samples. Free Radic Biol Med 2007; 43: 645-657.

48 Kleinbongard P, Dejam A, Lauer T, et al. Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans. Free Radic Biol Med 2006; 40: 295-302.

49 Lakatta EG, Yin FC. Myocardial aging: functional alterations and related cellular mechanisms. Am J Physiol 1982; 242: H927-H941.

50 Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study. Am J Cardiol 1971; 27: 335-346.

51 Ross, R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340: 115-126.

52 Soltis EE. Effect of age on blood pressure and membrane- dependent vascular responses in the rat. Circ Res 1987; 61: 889-897.

53 van der Loo B, Labugger R, Skepper JN, et al. Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med 2000; 192: 1731-1744.

54 Pie JE, Baek SY, Kim HP, et al. Age-related decline of inducible nitric oxide synthase gene expression in primary cultured rat hepatocytes. Mol Cells 2002; 13: 399-406.

55 Zhou XJ, Vaziri ND, Zhang J, et al. Association of renal injury with nitric oxide deficiency in aged SHR: prevention by hypertension control with AT1 blockade. Kidney Int 2002; 62: 914-921.

56 Berkowitz DE, White R, Li D, et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003; 108: 2000-2006.

57 Egashira K, Inou T, Hirooka Y, et al. Effects of age on endothelium-dependent vasodilation of resistance coronary artery by acetylcholine in humans. Circulation 1993; 88: 77-81.

58 Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81: 491-497.

59 Gerhard M, Roddy MA, Creager SJ, et al. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension 1996; 27: 849-853.

60 Lundberg JO, Gladwin MT, Ahluwalia A, et al. Nitrate and nitrite in biology, nutrition and therapeutics. Nat Chem Biol 2009; 5: 865-869.

61 Willmot M, Ghadami A, Whysall B, et al. Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension 2006; 47: 1209-1215.

62 Kapil V, Milsom AB, Okorie M, et al. Inorganic nitrate supplementation lowers blood pressure in humans: role for nitrite-derived NO. Hypertension 2010; 56: 274-281.

63 Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-1478.

64 Lieberman EH, Gerhard MD, Uehata A, et al. Flow-induced vasodilation of the human brachial artery is impaired in patients < 40 years of age with coronary artery disease. Am J Cardiol 1996; 78: 1210-1214.

65 Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315: 1046-1051.

66 Creager MA, Cooke JP, Mendelsohn ME, et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990; 86: 228-234.

67 Celermajer DS, Sorensen KE, Georgakopoulos D, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993; 88: 2149-2155.

68 Faxon DP, Fuster V, Libby P, et al. Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation 2004; 109: 2617-2625.

69 Schächinger V, Britten MB, Zeiher AM, et al. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906.

70 Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005; 111: 363-368.

71 Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106: 653-658.

72 Bugiardini R, Manfrini O, Pizzi C, et al. Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms. Circulation 2004; 109: 2518-2523.

73 Halcox JP, Schenke WH, Zalos G, et al. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 2001; 104: 448-454.

74 Chen J, Kuhlencordt PJ, Astern J, et al. Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice. Circulation 2001; 104: 2391-2394.

75 Ozaki M, Kawashima S, Yamashita T, et al. Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest 2002; 110: 331-340.

76 Stokes KY, Dugas TR, Tang Y, et al. Dietary nitrite prevents hypercholesterolemic microvascular inflammation and reverses endothelial dysfunction. Am J Physiol Heart Circ Physiol 2009; 296: H1281-H1288.

77 Lundberg JO. Cardiovascular prevention by dietary nitrate and nitrite. Am J Physiol Heart Circ Physiol 2009; 296: H1221-H1223.

78 Loscalzo J. N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest 1985; 76: 703-708.

79 Pigazzi A, Heydrick S, Folli F, et al. Nitric oxide inhibits thrombin receptor-activating peptide-induced phosphoinositide 3-kinase activity in human platelets. J Biol Chem 1999; 274: 14368-14375.

80 Trepakova ES, Cohen RA, Bolotina VM. Nitric oxide inhibits capacitative cation influx in human platelets by promoting sarcoplasmic/endoplasmic reticulum Ca2+-ATPase-dependent refilling of Ca2+ stores. Circ Res 1999; 84: 201-209.

81 Mendelsohn ME, O'Neill S, George D, et al. Inhibition of fibrinogen binding to human platelets by S-nitroso-N- acetylcysteine. J Biol Chem 1990; 265: 19028-19034.

82 Sase K, Michel T. Expression of constitutive endothelial nitric oxide synthase in human blood platelets. Life Sci 1995; 57: 2049-2055.

83 Zhou Q, Hellermann GR, Solomonson LP. Nitric oxide release from resting human platelets. Thromb Res 1995; 77: 87-96.

84 Freedman JE, Loscalzo J, Barnard MR, et al. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 1997; 100: 350-356.

85 Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res, 2001; 88: 756-762.

86 Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-2117.

87 Corzo L, Zas R, Rodríguez S, et al. Decreased levels of serum nitric oxide in different forms of dementia. Neurosci Lett 2007; 420: 263-267.

88 Purnell C, Gao S, Callahan CM, et al. Cardiovascular risk factors and incident Alzheimer disease: a systematic review of the literature. Alzheimer Dis Assoc Disord 2009; 23: 1-10.

89 Dudzinski DM, Igarashi J, Greif D, et al. The regulation and pharmacology of endothelial nitric oxide synthase. Annu Rev Pharmacol Toxicol 2006; 46: 235-276.

90 Selkoe DJ. Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci 1994; 17: 489-517.

91 Gorevic PD, Goñi F, Pons-Estel B, et al. Isolation and partial characterization of neurofibrillary tangles and amyloid plaque core in Alzheimer's disease: immunohistological studies. J Neuropathol Exp Neurol 1986; 45: 647-664.

92 Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120: 885-890.

93 Puzzo D, Palmeri A, Arancio O. Involvement of the nitric oxide pathway in synaptic dysfunction following amyloid elevation in Alzheimer's disease. Rev Neurosci 2006; 17: 497-523.

94 Law A, O'Donnell J, Gauthier S, et al. Neuronal and inducible nitric oxide synthase expressions and activities in the hippocampi and cortices of young adult, aged cognitively unimpaired, and impaired Long-Evans rats. Neuroscience 2002; 112: 267-275.

95 Wilcock DM, Lewis MR, Van Nostrand WE, et al. Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J Neurosci 2008; 28: 1537-1545.

96 Wirtz-Brugger F, Giovanni A. Guanosine 3',5'-cyclic monophosphate mediated inhibition of cell death induced by nerve growth factor withdrawal and beta-amyloid: protective effects of propentofylline. Neuroscience 2000; 99: 737-750.

97 Paris D, Town T, Parker T, et al. Beta-Amyloid vasoactivity and proinflammation in microglia can be blocked by cGMP- elevating agents. Ann NY Acad Sci 2000; 903: 446-450.

98 Puzzo D, Vitolo O, Trinchese F, et al. Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. J Neurosci 2005; 25: 6887-6897.

99 Austin SA, Santhanam AV, Katusic ZS. Endothelial nitric oxide modulates expression and processing of amyloid precursor protein. Circ Res 2010; 107: 1498-1502.

100 Baltrons MA, Pedraza CE, Heneka MT, et al., Beta-amyloid peptides decrease soluble guanylyl cyclase expression in astroglial cells. Neurobiol Dis 2002; 10: 139-149.

101 Baltrons MA, Pedraza CE, Heneka MT, et al. Physiological levels of beta-amyloid induce cerebral vessel dysfunction and reduce endothelial nitric oxide production. Neurol Res 2001; 23: 506-512.

102 Bonkale WL, Winblad B, Ravid R, et al. Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease. Neurosci Lett 1995; 187: 5-8.

103 Qu J, Nakamura T, Cao G, et al. S-Nitrosylation activates Cdk5 and contributes to synaptic spine loss induced by {beta}-amyloid peptide. Proc Natl Acad Sci USA 2011; 108: 14330-14335.

104 Presley TD, Morgan AR, Bechtold E, et al. Acute effect of a high nitrate diet on brain perfusion in older adults. Nitric Oxide 2011; 24: 34-42.

105 World Health Organization. Report on diet, nutrition and the prevention of chronic diseases, 2003. mediacentre/news/releases/2003/pr20/en/ (accessed on September 24, 2011).

106 Larsson SC, Bergkvist L, Wolk A. Processed meat consumption, dietary nitrosamines and stomach cancer risk in a cohort of Swedish women. Int J Cancer 2006; 119: 915-919.

107 Larsson SC, Orsini N, Wolk A. Processed meat consumption and stomach cancer risk: a meta-analysis. J Natl Cancer Inst 2006; 98: 1078-1087.

108 van Loon AJ, Botterweck AA, Goldbohm RA, et al. Intake of nitrate and nitrite and the risk of gastric cancer: a prospective cohort study. Br J Cancer 1998; 78: 129-135.

109 Cross AJ, Freedman ND, Ren J, et al. Meat consumption and risk of esophageal and gastric cancer in a large prospective study. Am J Gastroenterol 2011; 106: 432-442.

110 Jakszyn P, Bingham S, Pera G, et al. Endogenous versus exogenous exposure to N-nitroso compounds and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study. Carcinogenesis 2006; 27: 1497-1501.

111 Jakszyn P, Gonzalez CA. Nitrosamine and related food intake and gastric and oesophageal cancer risk: a systematic review of the epidemiological evidence. World J Gastroenterol 2006; 12: 4296-4303.

112 Knekt P, Järvinen R, Dich J, et al. Risk of colorectal and other gastro-intestinal cancers after exposure to nitrate, nitrite and N-nitroso compounds: a follow-up study. Int J Cancer 1999; 80: 852-856.

113 Eichholzer M, Gutzwiller F. Dietary nitrates, nitrites, and N-nitroso compounds and cancer risk: a review of the epidemiologic evidence. Nutr Rev 1998; 56: 95-105.

114 Milkowski A, Garg HK, Coughlin JR, et al. Nutritional epidemiology in the context of nitric oxide biology: a risk-benefit evaluation for dietary nitrite and nitrate. Nitric Oxide 2010; 22: 110-119.

115 Alexander DD, Weed DL, Cushing CA, et al. Meta-analysis of prospective studies of red meat consumption and colorectal cancer. Eur J Cancer Prev 2011; 20: 293-307.

116 Truswell AS. Meat consumption and cancer of the large bowel. Eur J Clin Nutr 2002; 56 (Suppl 1): S19-S24.

117 Adami HO, Berry SC, Breckenridge CB, et al. Toxicology and epidemiology: improving the science with a framework for combining toxicological and epidemiological evidence to establish causal inference. Toxicol Sci 2011; 122: 223-234.

118 Cho E, Smith-Warner SA. Meat and fat intake and colorectal cancer risk: A pooled analysis of 14 prospective studies [Abstract]. Proc Amer Assoc Cancer Res 2004.

119 Boyle P, Boffetta P, Autier P. Diet, nutrition and cancer: public, media and scientific confusion. Ann Oncol 2008; 19: 1665-1667.